GlassScriptPhysician profile
Bradley P Everly
NPI 1053561993
$266,158.34
in general payments reported to CMS, 2019-2025
32 companies · $51K in 2025
The $51K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $18K · 2021: $18K · 2022: $59K · 2023: $55K · 2024: $52K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $157K · Food and Beverage: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $156,704.30 |
| Food and Beverage | $215.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $156,704.30 | 2023-2025 | |
| Csl Behring | $106,955.35 | 2019-2022 | |
| Novo Nordisk INC | $264.20 | 2020-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $236.57 | 2019-2022 | |
| Abbvie INC. | $228.96 | 2019-2025 | |
| Pfizer INC. | $219.28 | 2019-2022 | |
| Allergan, INC. | $158.81 | 2019-2020 | |
| Glaxosmithkline, LLC. | $156.89 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.49 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.84 | 2019-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $92.44 | 2019-2021 | |
| Amgen INC. | $87.54 | 2019-2021 | |
| Amarin Pharma, INC. | $84.50 | 2019-2021 | |
| Lilly USA, LLC | $78.70 | 2019-2024 | Zepbound |
| Kowa Pharmaceuticals America, INC. | $74.26 | 2020-2023 | Livalo, Seglentis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $72.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $69.63 | 2019-2022 | |
| Eisai INC. | $58.63 | 2021 | |
| Nestle Healthcare Nutrition INC. | $47.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.71 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $43.50 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $29.24 | 2020 | |
| Almatica Pharma LLC | $28.38 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $26.87 | 2021 | |
| Mannkind Corporation | $23.51 | 2019 | |
| Hikma Pharmaceuticals USA | $16.02 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.80 | 2019 | |
| Aimmune Therapeutics, INC. | $14.86 | 2025 | Zenpep |
| Harmony Biosciences LLC | $14.69 | 2023 | Wakix |
| Daiichi Sankyo INC. | $14.20 | 2021 | |
| Esperion Therapeutics, INC. | $12.84 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Everly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.